Pharmacologic targeting of ALKBH5 enhanced the anti-tumor efficacy of EGFR inhibitor erlotinib, suggesting that ALKBH5 may function as a potential therapeutic target in combination with EGFR for glioblastoma patients. Here, ALKBH5 is linked to neoplasm.